The ongoing, signal-seeking phase II portion of the phase II/III study evaluating Granite, a personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer, produced positive preliminary data.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe